Epidermal Growth Factor Promotes Proliferation and Improves Restoration After Intestinal Ischemia–Reperfusion Injury in Rats
- First Online:
- 273 Downloads
Epidermal growth factor (EGF) is an attractive and promising therapeutic application for intestinal disorders. The current study examined its influence on proliferation and restoration after ischemia–reperfusion (I/R) injury in rat small intestine. Six groups were performed: sham operation (Con); ischemia for 30 min with subsequent reperfusion for 30 min (I/R); I/R injured with 500 μg/kg EGF injected 5 min before ischemia (Pre-l); I/R injured with 50 μg/kg EGF injected 5 min before ischemia (Pre-s); I/R injured with 500 μg/kg EGF injected 5 min after reperfusion (Post-l); and I/R injured with 50 μg/kg EGF injected 5 min after reperfusion (Post-s). Intestinal histological damage, crypt cell proliferation degree, mucosal permeability, tight junction proteins expression, and levels of inflammation factors were studied for each group. Compared with the I/R group, administration of EGF in the Pre-l, Pre-s, and Post-l groups all presented a significant proliferation effect. The levels of FD4, IL-6, and TNF-α were dramatically decreased in all EGF-treated groups. Histological destruction was improved and TJs recovery was notably accelerated in all EGF-treated groups except the Post-s group. d-lactate concentration was only diminished in the Pre-l group. These results suggest that mucosally applied EGF can promote intestinal proliferation and improve restoration after I/R injury. EGF intraluminal administration is an effective treatment against intestinal I/R injury.
KEY WORDSepidermal growth factor ischemia–reperfusion proliferation intestinal barrier function recovery
- 5.Geng, Y., J. Li, Q. Li, and L. Sun. 2012. Role of proliferation in the recovery of intestinal mucosal function after ischemia–reperfusion injury in rats. Parenteral and Enteral Nutrition 19: 288–292.Google Scholar
- 22.Clark, J.A., H. Gan, A.J. Samocha, A.C. Fox, T.G. Buchman, and C.M. Coopersmith. 2009. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. American Journal of Physiology–Gastrointestinal and Liver Physiology 297: G471–G479.PubMedCrossRefGoogle Scholar
- 24.Palomino, A., F. Hernandez-Bernal, W. Haedo, et al. 2000. A multicenter, randomized, double-blind clinical trial examining the effect of oral human recombinant epidermal growth factor on the healing of duodenal ulcers. Scandinavian Journal of Gastroenterology 35: 1016–1022.PubMedCrossRefGoogle Scholar